ArticleTherapeutic advances in medical oncology2025
Neutrophil extracellular traps predict poor response and prognosis in non-small cell lung cancer immunotherapy.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Prognostic significance of intratumoral neutrophil extracellular traps in pulmonary pleomorphic carcinoma: comparison with adenocarcinoma.BJC reports · 2026Article
- Roles of neutrophil extracellular traps in cancer immunotherapy resistance and therapeutic targeting.Biomarker research · 2026Review
- The Neutrophil-NET Axis in Immune Checkpoint Inhibitor Resistance in Non-Small Cell Lung Cancer: Roles, Biomarkers and Therapeutic Opportunities.Biomolecules · 2026Review
- Immunosuppressive cells as barriers to cancer therapy: mechanisms and emerging solutions.Frontiers in immunology · 2026Review
- Tumor immune microenvironment in non-small cell lung cancer progression.Frontiers in immunology · 2026Review
- Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have improved outcomes in non-small cell lung cancer (NSCLC), yet reliable biomarkers for predicting response remain limited. Neutrophil extracellular traps (NETs) may influence tumor immunity, but their clinical significance in NSCLC is unclear. Objectives: To evaluate the predictive and prognostic value of NETs in advanced NSCLC patients treated with chemo-immunotherapy. Design: A retrospective cohort study. Methods: Pretreatment formalin-fixed paraffin-embedded biopsies from 46 stage IV NSCLC patients receiving first-line chemo-immunotherapy were analyzed by multiplex immunofluorescence to quantify NETs, CD8 Results: High NETs' density was associated with shorter progression-free survival (PFS: 8 vs 20 months, Conclusion: NETs predict poor immunotherapy response and survival in advanced NSCLC and interact with CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.